BUSINESS

Shionogi Gets New Oral COVID-19 Drug into Clinic in Less than 1 Year, Now Gearing Up for PII/III

September 24, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Shionogi is developing an oral drug for COVID-19 at a pace that was unthinkable prior to the coronavirus pandemic. Other companies have repurposed molecules previously developed for other infections such as SARS and MARS, but Shionogi is attempting to develop…

To read the full story

Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
Shionogi’s COVID-19 Pill Improves Respiratory and Feverish Symptoms
April 26, 2022
Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
Japan Inks Supply Deal for Shionogi’s COVID Pill for 1 Million People
March 25, 2022
FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
Japan to Expedite Review for Shionogi’s COVID-19 Pill: PM
March 1, 2022
Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
Lawmakers Mixed on Use of Conditional Approval for Shionogi’s COVID-19 Pill
February 16, 2022
MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
Shionogi Looks to File COVID Pill in Japan as Early as Next Week
February 8, 2022
Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
Shionogi’s COVID-19 Pill Submission Delaying into 2022 as Recruitment Hits Snag
January 6, 2022
Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
Shionogi Chief Expresses Eagerness for COVID-19 Drug Rollout, PII/III to Wrap Up by Year-End
September 30, 2021
Shionogi Kicks Off Japan PII/III Trial for Oral COVID-19 Drug
September 29, 2021
Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President
September 24, 2021
Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021

BUSINESS

Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
Espha Launches Generic Forxiga; Nipro AG Due in September
July 6, 2026
GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

COMMENTARY

New Generic Listings Plunge, Industry Heads for a Shakeout

By Tatsuya Otsuka

The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…